EODev, the French clean energy company specialising in hydrogen power generation and energy storage systems, partnered with Baudouin, a French manufacturer of power solutions, to introduce industrial-scale Solid Oxide Fuel Cell (SOFC) power generation systems. The strategic alliance marks a significant step towards delivering a new generation of high-efficiency distributed power solutions designed to meet the growing energy needs of data centres, industrial facilities, and critical infrastructure. The companies will officially unveil the new offering in September 2026.

Partnership Targets Growing Demand for Reliable Distributed Power

As electricity demand continues to rise across Europe, operators of data centres, manufacturing plants, and essential infrastructure face increasing challenges in securing reliable power. Grid congestion, lengthy connection delays, and the transition towards renewable energy have intensified the need for dependable on-site electricity generation. To address these challenges, EODev and Baudouin are combining their expertise to provide distributed power systems capable of delivering continuous, reliable, and lower-carbon electricity.

Solid Oxide Fuel Cells Deliver Efficient, Low-Carbon Power

At the heart of the partnership is Solid Oxide Fuel Cell (SOFC) technology, which generates electricity through an electrochemical process rather than combustion. SOFC systems can operate using natural gas, renewable gases, or hydrogen, offering greater fuel flexibility while significantly reducing greenhouse gas emissions.

Key benefits of SOFC technology include high electrical efficiency, lower carbon dioxide (CO₂) emissions, near-zero air pollutant emissions, quiet and continuous operation, grid-connected or
off-grid capability and waste heat recovery for combined heat and power (CHP) applications. Consequently, SOFC technology provides an ideal solution for organisations seeking dependable, around-the-clock power while advancing their decarbonisation goals.

Expanding EODev’s Clean Energy Portfolio

For EODev, the partnership complements its existing portfolio of hydrogen generators and battery energy storage systems (BESS) by adding a continuous baseload power solution. Unlike intermittent renewable energy sources, SOFC systems provide uninterrupted electricity generation, making them well suited for facilities that require constant power availability. Each standard SOFC unit delivers 600 kW of power and can be combined into multi-megawatt installations to meet the energy requirements of large industrial and commercial sites.

Baudouin Strengthens Its New Energy Strategy

The collaboration also enables Baudouin to expand its expertise beyond conventional power generation by entering the rapidly growing fuel cell market. By integrating advanced SOFC technology into its product portfolio, the company strengthens its position in next-generation energy solutions while continuing to support customers with reliable and high-performance power systems.

Management Comments

Stéphane Jardin, Chief Executive Officer of EODev, said, “Our customers are not looking for a specific technology. They want power they can count on, that fits their site and helps them cut emissions. SOFC allows us to offer high-efficiency, lower-carbon power that operates continuously on-site. Partnering with Baudouin provides us with a trusted industrial partner to bring this solution to market with the quality and support our customers expect.”

Fabrizio Mozzi, Chief Executive Officer of Baudouin, added, “The partnership with EODev represents an important milestone in Baudouin’s New Energy journey. By combining our expertise in critical power applications with innovative Solid Oxide Fuel Cell technology, we are expanding the range of solutions available to our customers while remaining committed to reliability, performance, and the long-term energy transition.”

Commercial Rollout Planned for 2026

Under the agreement, EODev will integrate Baudouin’s SOFC solutions across Europe, holding exclusive distribution rights in France and Poland, while jointly exploring opportunities in international markets. The technology is currently undergoing field validation through pilot installations. Following successful trials, the companies plan to officially launch the solution in September 2026, with the first commercial customer deliveries expected in the first quarter of 2027.

Supporting the Future of Distributed Energy

The partnership reflects the growing demand for resilient, low-carbon distributed power systems capable of supporting industrial operations, data centres, and mission-critical infrastructure. As per the press release, by combining hydrogen-ready fuel cell technology with proven industrial expertise, EODev and Baudouin aim to deliver scalable, energy-efficient solutions that help customers improve energy security while accelerating the transition to cleaner power generation.

Brenntag, the global player in chemicals and ingredients distribution, signed a new distribution agreement with BASF to strengthen the availability of innovative cleaning solutions across Sub-Saharan Africa. The partnership expands Brenntag’s specialty portfolio for the Home Care and Industrial & Institutional (I&I) Cleaning sectors in South Africa, Nigeria, Ghana, Kenya, Uganda, Tanzania, and Ethiopia. The agreement aims to provide customers with high-performance, sustainable cleaning ingredients while supporting the growing demand for advanced hygiene and cleaning solutions across the region.

Expanding Access to Advanced Cleaning Solutions

Through the new collaboration, Brenntag will distribute BASF’s broad portfolio of innovative cleaning ingredients, enabling manufacturers to develop high-performance formulations for household and industrial cleaning applications. Leveraging its extensive market expertise, robust supply chain, and established distribution network, Brenntag will help customers gain easier access to BASF’s advanced technologies across multiple African markets.

Comprehensive Portfolio for Home Care and I&I Applications

BASF’s cleaning solutions are designed to enhance the performance of a wide range of Home Care and Industrial & Institutional (I&I) Cleaning products. The portfolio features advanced surfactant systems that effectively remove grease, dirt, and other common contaminants while improving formulation stability. In addition, these ingredients help manufacturers achieve their sustainability objectives without compromising cleaning performance. As a result, customers can formulate reliable, efficient, and environmentally responsible cleaning products that meet evolving market expectations.

Innovative Ingredients for Laundry Care

Beyond surface cleaning, BASF’s portfolio also offers advanced ingredients specifically developed for laundry care applications. These solutions help improve stain removal performance, fabric protection, colour retention and cleaning efficiency at lower wash temperatures. Consequently, laundry formulations can deliver excellent cleaning results while reducing energy consumption, supporting both cost savings and sustainability goals.

Meeting Growing Hygiene and Sustainability Demands

The partnership enables Brenntag and BASF to deliver scalable, high-performance cleaning solutions that address the increasing demand for hygiene, efficiency, and environmental responsibility across Sub-Saharan Africa. The collaboration allows both companies to broaden customer access to innovative technologies while strengthening technical support and local market presence.

Brenntag Strengthens Its Specialty Portfolio

By adding BASF’s advanced cleaning ingredients to its portfolio, Brenntag reinforces its position as a leading specialty chemicals distributor for the Home Care and Industrial & Institutional Cleaning industries. The expanded offering provides customers with greater formulation flexibility, reliable product performance, and access to globally recognised technologies.

Management Perspective

Kreason Gopalan, Regional Commercial Director, Sub-Saharan Africa, Brenntag Specialties Beauty & Care, said, “We are proud to partner with BASF to deliver high-performance, innovative cleaning solutions across Sub-Saharan Africa. Their advanced portfolio enables our customers to develop high-performing cleaning formulations in Home Care and Industrial & Institutional applications while aligning with growing sustainability expectations. This collaboration strengthens our commitment to bringing effective, reliable, and future-ready solutions to the markets we serve.”

Marton Nick, Head of Regional Sales Home Care and I&I Cleaning – CEE, Africa and Middle East, BASF, added, “Sub-Saharan Africa is an important growth region for the Home Care and Industrial & Institutional Cleaning industry. Through our partnership with Brenntag, we are expanding customer access to BASF’s innovative solutions while strengthening local support and technical expertise across key markets in the region.”

Strengthening the Cleaning Solutions Market in Africa

The new distribution agreement marks another step in Brenntag’s strategy to expand its specialty chemicals portfolio while supporting BASF’s regional growth ambitions. As per the press release, together, the two companies aim to help manufacturers develop innovative, sustainable, and high-performance cleaning products that address the evolving needs of consumers and industries across Sub-Saharan Africa.

Midwest Energy commissioned a 1.2 GWh per annum Battery Energy Storage System (BESS) manufacturing facility in Bengaluru, marking a significant milestone in India’s growing clean energy and energy storage sector. The new plant is designed to support the country’s increasing demand for advanced battery storage solutions as renewable energy capacity continues to expand. With this investment, the company aims to strengthen domestic manufacturing capabilities while contributing to India’s energy transition and grid modernisation.

₹100 Crore Investment to Drive Manufacturing Growth

Midwest Energy has invested approximately ₹100 crore in establishing the state-of-the-art manufacturing facility. At full capacity utilisation, the plant is expected to generate annual revenues of nearly ₹1,000 crore. Additionally, the facility is projected to create 150 to 250 employment opportunities as production scales up, supporting skilled workforce development in India’s clean energy manufacturing sector.

Comprehensive Battery Storage Solutions

The Bengaluru facility manufactures a wide range of Battery Energy Storage Systems (BESS) with capacities ranging from 3 kWh to 6 MWh across voltage platforms from 48V to 1,500V. The facility is well-positioned to address the growing need for reliable, efficient and scalable energy storage systems across multiple sectors. The new manufacturing unit features integrated cell-to-container production capabilities, enabling Midwest Energy to streamline the entire battery storage manufacturing process under one roof. The facility produces battery systems that comply with internationally recognised safety standards.

Expansion Plans to Reach 6 GWh Capacity

Building on the initial 1.2 GWh capacity, Midwest Energy plans to automate the existing manufacturing facility to increase production to 2 GWh. The company has also outlined an ambitious expansion roadmap to further scale manufacturing capacity to 3 GWh and ultimately 6 GWh over the next three years. This phased expansion reflects the company’s long-term commitment to supporting India’s rapidly growing energy storage market.

Supporting India’s Renewable Energy Transition

The commissioning of the new BESS manufacturing facility aligns with India’s accelerating adoption of renewable energy and the increasing need for reliable energy storage infrastructure. As solar and wind power installations continue to grow, battery energy storage systems will play a crucial role in enhancing grid stability, improving energy reliability and enabling greater integration of renewable power. As reported by projectstoday.ai, with its advanced manufacturing capabilities and expansion strategy, Midwest Energy is well-positioned to contribute to India’s clean energy ambitions while strengthening the country’s domestic battery storage manufacturing ecosystem.

The government unveiled an ambitious roadmap to position the country as a global biotechnology leader by 2035. Alongside the launch of the strategic roadmap, ‘Building India as a Leading Bioeconomy Powerhouse by 2035,’ Union Minister for Science and Technology Dr. Jitendra Singh announced the country’s first undergraduate programme in Engineering Biology. The initiative marks a significant milestone in India’s biotechnology journey and aims to create a future-ready workforce capable of driving innovation in healthcare, agriculture, industrial biotechnology and sustainable manufacturing.

Engineering Biology to Power the Next Biotechnology Revolution

Dr. Jitendra Singh described Engineering Biology as a transformative discipline that will play a role similar to that of computer science during the digital revolution. He emphasised that India must develop an independent and globally competitive biotechnology ecosystem by nurturing professionals with expertise at the intersection of engineering, biology, medicine and emerging technologies. “We have to build our own independent, sovereign biotechnology ecosystem,” the minister said. He further revealed that several Indian Institutes of Technology (IITs) have already submitted proposals to introduce interdisciplinary Engineering Biology programmes in collaboration with leading medical institutions.

India’s Bioeconomy Witnesses Remarkable Growth

Highlighting the sector’s rapid expansion, Dr. Singh noted that India’s bioeconomy has grown from nearly $10 billion in 2014 to approximately $95 billion today. The government expects the sector to reach $300 billion by 2030, supported by strong research capabilities, expanding industrial applications and a vibrant innovation ecosystem. India is also home to more than 11,000 biotechnology start-ups, making it one of the world’s fastest-growing biotechnology innovation hubs.

Dedicated Biotechnology Policy Drives Innovation

According to the minister, India remains among the few nations with a dedicated biotechnology policy focused on Biotechnology for Economy, Employment and Environment. The policy encourages faster translation of scientific research into commercial products, economic growth and societal benefits while strengthening India’s competitiveness in global biotechnology markets. Dr. Singh highlighted India’s achievements in healthcare biotechnology, citing the development of the world’s first DNA vaccine against COVID-19 and the country’s role in supplying vaccines to nearly 30 countries. He also pointed to India’s growing expertise in advanced therapies. These innovations are making cutting-edge healthcare more accessible while reinforcing India’s position as a preferred destination for affordable, high-quality medical treatments.

Synthetic Biology and AI to Shape the Future

Looking ahead, the minister identified several emerging technologies that will define the next phase of biotechnology growth. These include synthetic biology, Artificial Intelligence (AI)-enabled biological research, bio-manufacturing, protein engineering, next-generation therapeutics, sustainable food systems and clean fuels and bio-based chemicals. Collectively, these technologies are expected to transform multiple industries while supporting India’s transition towards a sustainable and innovation-driven economy.

Industry Collaboration Remains Critical

Dr. Singh stressed that stronger collaboration between scientists, entrepreneurs, manufacturers and research institutions will be essential for accelerating innovation. Such initiatives will help create a highly skilled workforce capable of supporting India’s long-term biotechnology ambitions.

Building India’s Global Biotechnology Leadership

Dr. Jitendra Singh stated that the coming decade will be decisive for India’s biotechnology sector. He expressed confidence that sustained investments in research, innovation, education and industry partnerships will strengthen healthcare, improve food security, generate millions of high-skilled jobs and establish India as one of the world’s leading bioeconomy powerhouses. As reported by ddindia.co.in, with the launch of its first Engineering Biology undergraduate programme and a long-term biotechnology roadmap, India has taken a major step towards building a resilient, innovation-driven and globally competitive bioeconomy.

The government is set to invest ₹10,000 crore to strengthen the country’s biopharmaceutical ecosystem and accelerate the transition from a global generic medicines hub to a leading innovator in biologics and biosimilars. The proposed Biopharma SHAKTI scheme aims to build domestic capabilities for discovering, testing and scaling advanced biological medicines. According to Manoj Joshi, Secretary, Department of Pharmaceuticals, the scheme’s operational guidelines are in the final stages and will be released after receiving the necessary approvals, including clearance from the Union Cabinet. Subsequently, the government will invite proposals from pharmaceutical companies as well as industry-academia collaborations.

Bridging India’s Biologics Capability Gap

While India has established itself as one of the world’s largest producers of generic medicines, it still lacks adequate infrastructure and expertise to develop complex biological drugs from discovery to commercial production. The Biopharma SHAKTI scheme seeks to bridge this gap by creating an integrated ecosystem that supports the complete biologics development pipeline. As healthcare demands shift towards advanced therapies for chronic and life-threatening diseases, the initiative aims to position India as a significant player in the global biologics market.

Supporting Next-Generation Therapies

Proposed in the Union Budget 2026-27, the ₹10,000 crore programme will be implemented over five years and will support the development of innovative biologics along with the infrastructure required for research, clinical validation and commercialisation. The scheme will focus on novel biologics, biosimilars, monoclonal antibodies, CAR-T cell therapies and advanced cellular therapies.  Additionally, the government plans to expand India’s clinical trial network and promote the adoption of electronic health records to strengthen medical research and patient data management.

Targeting a Larger Share of the Global Biopharma Market

Biologics are sophisticated medicines produced using living organisms, while biosimilars are highly similar versions of already approved biologic drugs. These therapies are increasingly being used to treat cancer, autoimmune disorders, metabolic diseases and other chronic illnesses. With the new initiative, the government aims to secure a 5% share of the global biopharmaceutical market, capitalising on the growing international demand for high-value biological therapies. According to the India Brand Equity Foundation (IBEF), India’s biopharma market is currently valued at approximately $64.5 billion, highlighting significant growth opportunities.

Strengthening CRDMOs and Domestic Research Infrastructure

A key pillar of the Biopharma SHAKTI scheme is the development of India’s Contract Research, Development and Manufacturing Organisations (CRDMOs). These specialised organisations play a critical role in biological molecule synthesis, structural characterisation, preclinical testing, clinical development, process optimisation and commercial-scale manufacturing.  Currently, India depends heavily on overseas facilities for advanced synthetic biology capabilities and clinical research. Therefore, the scheme aims to reduce this dependence by supporting domestic CRDMOs through research grants, shared state-of-the-art facilities and partnerships with state governments to reduce infrastructure, power and utility costs.

Industry-Academia Collaboration to Drive Innovation

The Department of Pharmaceuticals has conducted extensive consultations with stakeholders across the pharmaceutical and biotechnology ecosystem while designing the scheme. These consultations included Indian Council of Medical Research (ICMR), Department of Biotechnology (DBT), Biotechnology Industry Research Assistance Council (BIRAC), National Institute of Pharmaceutical Education and Research (NIPER), government research laboratories, pharmaceutical companies and academic institutions. According to Manoj Joshi, the scheme incorporates industry requirements and market needs to ensure that India develops globally competitive biologics research capabilities.

Focus Beyond Manufacturing

Unlike earlier initiatives that primarily encouraged pharmaceutical manufacturing, Biopharma SHAKTI places greater emphasis on the entire drug development lifecycle. Developing biologics involves significantly more complex processes than manufacturing conventional chemical-based medicines. Researchers must identify promising biological molecules, validate their effectiveness, manufacture laboratory batches, conduct animal safety studies and complete multiple phases of human clinical trials before commercial production. The government intends to strengthen every stage of this value chain, enabling Indian companies to move from manufacturing generic medicines to developing innovative biological therapies.

AI to Complement, Not Replace, Drug Development

The government also expects Artificial Intelligence (AI) to accelerate biologics discovery by helping researchers identify promising drug candidates more efficiently. However, officials emphasise that AI alone cannot replace specialised research infrastructure. Advanced CRDMOs will remain essential for producing experimental molecules, conducting preclinical studies, validating safety and efficacy, and scaling biological products for clinical trials and commercial manufacturing.

Positioning India as a Global Biologics Hub

Through the Biopharma SHAKTI initiative, India aims to build a robust innovation ecosystem that supports research, clinical development and commercial manufacturing of advanced biological medicines. As reported by livemint.com, by strengthening domestic capabilities and reducing reliance on overseas facilities, the government seeks to transform India into a global hub for biologics, biosimilars and next-generation biopharmaceutical innovation.

Adani Enterprises Ltd. partnered with French clean technology company Dioxycle to establish low-carbon chemical manufacturing in India. The collaboration will begin with a pilot plant that produces formic acid using captured carbon dioxide (CO₂) and renewable electricity, marking a significant step towards sustainable chemical production. The pilot facility will be set up at an Adani Group site. If the project successfully demonstrates the technology’s commercial viability, the partners plan to scale up production and expand the use of carbon-based green chemicals across multiple industries.

Pilot Plant to Convert Captured CO₂ into Valuable Chemicals

The project aims to showcase how captured carbon emissions can be transformed into high-value industrial chemicals using renewable energy instead of fossil fuels. By combining carbon capture with clean electricity, the initiative seeks to reduce greenhouse gas emissions while creating a sustainable source of essential chemicals. Initially, the facility will focus on manufacturing formic acid, a versatile industrial chemical widely used in textile processing, agriculture, leather manufacturing, chemical processing and industrial cleaning applications.  The technology represents an innovative approach to carbon utilisation, turning waste emissions into commercially valuable products.

Adani Expands Its Clean Technology Portfolio

With this partnership, Adani Group enters the low-carbon chemicals sector, expanding its sustainability portfolio beyond renewable energy, infrastructure and green hydrogen initiatives. The companies plan to explore the production of additional industrial chemicals used in sectors such as energy, advanced materials, packaging, manufacturing and industrial processing.  Many of these chemicals are currently produced using fossil fuel-based feedstocks. Consequently, the collaboration could help reduce the chemical industry’s dependence on conventional carbon-intensive manufacturing processes.

Renewable Electricity Powers Sustainable Chemical Production

Unlike traditional chemical manufacturing, Dioxycle’s proprietary technology uses renewable electricity and captured carbon dioxide instead of fossil fuels to produce industrial chemicals. As a result, the process significantly lowers carbon emissions while supporting the transition towards cleaner and more sustainable manufacturing. By integrating renewable energy with carbon capture and utilisation (CCU), the technology also strengthens circular carbon economy practices and supports global decarbonisation goals.

Leadership Highlights

Jeet Adani, Director, Adani Group, said, “We are proud to pilot India’s first formic acid production facility powered entirely by renewable electricity and captured carbon. This partnership with Dioxycle demonstrates how strategic industrial synergies can transform carbon liabilities into sustainable and cost-effective economic assets.”

Sarah Lamaison, Chief Executive Officer and Co-founder of Dioxycle, said, “The partnership demonstrates how clean technology and industrial scale can come together to reshape how essential chemicals are produced. India offers a unique combination of renewable energy, manufacturing capability and ambition. Together with Adani, we aim to build a competitive and scalable model for low-carbon chemical production.”

Strengthening India-Europe Collaboration in Clean Technologies

Beyond technological innovation, the partnership reflects the growing collaboration between India and Europe in advancing clean technologies and sustainable manufacturing. As global industries seek lower-carbon supply chains and greener production methods, initiatives such as this are expected to accelerate the adoption of carbon capture, renewable energy integration and circular chemical manufacturing. As reported by msn.com, by combining Adani Group’s industrial capabilities with Dioxycle’s clean technology expertise, the partnership aims to position India as a future hub for low-carbon chemicals, supporting both industrial growth and climate action.

Attero, one of India’s largest critical minerals company and one of the world’s most advanced urban mining firms, successfully completed an independently verified Life Cycle Assessment (LCA) in accordance with ISO 14040:2021 and ISO 14044:2021 standards. The achievement establishes scientifically validated environmental performance data for metals recovered through the company’s e-waste and lithium-ion battery recycling operations.

As a result, Attero can now provide customers with product-specific, independently verified environmental data for its recycled metals. This enables businesses to accurately compare the environmental benefits of urban mining with those of conventional virgin mining. With industries increasingly focusing on ESG goals, sustainable procurement and Scope 3 emissions reduction, access to credible environmental data has become a critical factor in sourcing decisions.

Scientifically Measuring the Environmental Impact

Life Cycle Assessment is globally recognised as one of the most comprehensive methods for evaluating the environmental footprint of a product throughout its life cycle. Using internationally accepted scientific methodologies, Attero’s assessment quantifies the environmental performance of recovered metals, including aluminium, copper, iron, zinc, tin, silver and gold.

The assessment measures key environmental indicators such as carbon footprint, resource depletion, acidification, eutrophication, ecotoxicity, human toxicity and fossil resource consumption Importantly, the study compares these impacts with those associated with conventionally mined virgin metals, offering customers a transparent and scientifically validated sustainability benchmark.

Supporting ESG and Responsible Sourcing

The ISO-verified LCA allows customers to move beyond generic sustainability claims and industry averages. Instead, they gain access to independently verified environmental performance data that enables direct, like-for-like comparisons between recycled and virgin metals. Consequently, organisations can strengthen ESG reporting, Scope 3 emissions accounting, green procurement initiatives, Product Environmental Declarations (EPDs), regulatory environmental disclosures and sustainable supply chain reporting. As global regulations become more stringent and investors demand greater transparency, verified environmental data is rapidly becoming an essential business requirement.

Urban Mining Drives the Circular Economy

Nitin Gupta, Co-Founder and CEO of Attero, said, “The circular economy requires more than recycling; it requires measurable proof of environmental impact. This independently verified Life Cycle Assessment allows us to provide customers with scientifically validated environmental data for the metals we recover, enabling informed sourcing decisions and stronger sustainability reporting.” He further added that as industries seek responsible and sustainable sources of critical minerals, verified environmental performance will become as important as product quality, purity and traceability. According to him, the milestone reinforces urban mining as a scalable and sustainable solution for meeting the world’s growing demand for critical materials.

Advanced Technology Powers High Recovery Rates

Attero has established itself as a technology leader in critical minerals recovery through continuous investment in research and innovation. The company holds more than 50 global patents and has developed proprietary technologies to recover valuable metals from complex e-waste and lithium-ion battery waste streams.

Its advanced recycling processes achieve:

Up to 98% metal recovery efficiency

More than 99.9% purity in recovered materials

Recovery of strategic materials including lithium, cobalt, nickel, graphite, copper, gold and silver

These capabilities not only reduce dependence on conventional mining but also strengthen domestic supplies of critical minerals required for clean energy, electronics and advanced manufacturing.

Enhancing Transparency in Sustainable Supply Chains

With this ISO-verified Life Cycle Assessment, Attero further strengthens its leadership in the circular economy. Every tonne of recycled metal is now backed by independently verified environmental intelligence, providing customers with greater confidence in their sustainability claims. As per the press release, the verified data improves transparency across the value chain, helping manufacturers, OEMs and industrial buyers make informed sourcing decisions while supporting climate goals and resource efficiency. As industries continue their transition towards circular and low-carbon business models, Attero’s latest achievement positions the company as a trusted partner for sustainable critical minerals and responsible urban mining.

India emerged as the world’s fourth-largest liquefied natural gas (LNG) regasification market, achieving a total regasification capacity of 52.5 million tons per annum (MTPA) in 2025. According to the International Gas Union’s (IGU) World LNG Report 2026, the country has overtaken Spain, underscoring its growing influence in the global LNG value chain. With this milestone, India now ranks behind only Japan, China, and South Korea, reflecting sustained investments in LNG infrastructure and the country’s commitment to strengthening energy security while supporting a cleaner energy transition.

Regasification Infrastructure Continues to Expand

India’s LNG infrastructure has witnessed significant expansion over the past year. The Dahej LNG terminal remains the country’s largest regasification facility with a capacity of 17.5 MTPA, while the remaining seven operational terminals each have capacities of around 5 MTPA.

In 2025, India commissioned two major projects that further enhanced its LNG network:

The Chhara LNG terminal was commissioned with a capacity of 5 MTPA.

The Dabhol LNG terminal expanded its capacity from 2.9 MTPA to 5 MTPA following the completion of advanced breakwater infrastructure.

Notably, the upgraded Dabhol terminal can now operate throughout the year, eliminating seasonal disruptions caused by the southwest monsoon and significantly improving operational efficiency.

Utilisation Rate Declines Despite Capacity Growth

While India’s regasification capacity has increased substantially, terminal utilisation declined during 2025. According to the report, the country’s LNG regasification utilisation rate dropped to approximately 47%, compared with 58% in 2024. The decline primarily resulted from lower LNG imports during the summer months and the commissioning of additional regasification infrastructure, which temporarily outpaced demand growth. Despite the lower utilisation, the expanded infrastructure provides India with greater operational flexibility to meet future energy demand.

More LNG Projects Under Development

India’s LNG expansion is set to continue over the next few years. Currently, four LNG infrastructure projects are under construction, comprising one new regasification terminal and three capacity expansion projects at existing facilities. Together, these projects are expected to add 11.3 MTPA of regasification capacity by 2028, further strengthening India’s LNG import and distribution capabilities.

Global LNG Market Faces Geopolitical Challenges

The World LNG Report 2026 also highlights growing geopolitical uncertainties affecting global LNG markets. Escalating tensions in West Asia continue to pose risks to LNG supply chains and infrastructure. However, the report notes that the global LNG market has become more resilient due to a diversified supply base and increased flexibility in spot cargo trading. According to Andrea Stegher, President of the International Gas Union, disruptions in the Gulf region have created uncertainty for Asian LNG buyers and influenced global pricing. Nevertheless, the growing availability of spot LNG cargoes has helped mitigate immediate supply risks and improve market resilience.

Energy Security Drives India’s LNG Expansion

India’s expanding LNG regasification capacity reflects its long-term strategy to enhance energy security, diversify fuel sources, and accelerate the transition toward cleaner energy. As the country’s economy continues to grow and urbanisation accelerates, natural gas is expected to play an increasingly important role in meeting industrial, commercial, and residential energy demand. Operational improvements at key terminals, particularly Dabhol, will enable more reliable LNG supplies while strengthening India’s ability to respond to seasonal demand fluctuations and supply disruptions. As reported by indianewsweek.com, India’s emergence as the fourth-largest LNG regasification market marks a significant milestone in its energy infrastructure development. The ongoing expansion of LNG terminals and regasification capacity is expected to improve supply reliability, support industrial growth, and advance the country’s clean energy objectives.

India’s pharmaceutical and life sciences sector is rapidly transforming into a global innovation hub, with nearly ten novel drug molecules developed over the past decade, according to a joint report by Boston Consulting Group (BCG) and HealthKois. The report highlights India’s growing focus on scientific discovery while emphasizing the need to strengthen funding and research infrastructure to sustain long-term growth.

Companies are increasingly adopting diverse innovation strategies to compete globally. Notable examples include Glenmark Pharmaceuticals’ out-licensing agreement with AbbVie, which secured an upfront payment of US$700 million along with potential milestone payments of up to US$1.2 billion. Meanwhile, startups such as ImmunoACT are advancing cutting-edge CAR-T cell therapies, demonstrating India’s expanding capabilities in advanced biotechnology.

Drug Discovery Pipeline Expands Significantly

The report reveals a remarkable increase in India’s pharmaceutical innovation pipeline. Drug discovery programmes have grown by 1.5 times, reaching more than 1,095 programmes across 195 companies. At the same time, pharmaceutical patent families originating from India increased from approximately 716 in 2015 to 2,995 in 2024, raising India’s share of global pharma patents from 3-4% to nearly 10%. According to the report, this growth reflects not only higher volumes but also a significant improvement in the quality and impact of innovation.

Government Support Strengthens the Innovation Ecosystem

The report identifies over US$5 billion in government funding for early-stage and translational research as a major catalyst. In addition, stronger industry-academia collaborations, enhanced technology transfer mechanisms, and regulatory reforms have significantly improved the innovation landscape. Importantly, regulatory changes have reduced drug development approval timelines from 180-270 days to just 60-120 days, enabling companies to bring innovative therapies to market faster. Furthermore, world-class research and manufacturing hubs such as Genome Valley and Centre for Cellular and Molecular Platforms (C-CAMP) continue to provide shared infrastructure that supports pharmaceutical and biotechnology innovation.

Breakthrough Therapies Showcase India’s Research Capabilities

India is already witnessing encouraging examples of successful lab-to-market translation. Among the notable breakthroughs is BIRSA 101, India’s first indigenously developed CRISPR-based therapeutic, representing a major milestone in gene-editing technology. Another significant achievement is NexCAR19, an indigenous CAR-T cell therapy priced at nearly one-tenth of comparable international treatments, making advanced cancer therapies substantially more affordable. These developments underscore India’s growing capability to develop globally competitive, high-impact healthcare innovations.

Investment in Biotech Continues to Rise

Investor confidence in India’s life sciences sector is also strengthening. Private equity and venture capital investments in pharmaceuticals increased 2.1 times over the past five years, reaching US$731 million during the financial year ending March 2026. Simultaneously, the country’s biotechnology startup ecosystem expanded from approximately 1,500 startups to 2,400, reflecting growing entrepreneurial activity and increased interest in healthcare innovation.

Funding and Clinical Research Gaps Remain

Despite this progress, the report highlights several challenges that continue to limit India’s full innovation potential.mIndia currently accounts for only around 4% of global clinical trials, while annual pharmaceutical R&D expenditure remains between US$2-3 billion, significantly lower than the US$70-75 billion invested annually in the United States. Addressing these funding and research gaps will be essential for India to establish itself as a leading global pharmaceutical innovation centre.

Industry Leaders See a Shift Towards Scientific Discovery

Priyanka Aggarwal, Managing Director and Senior Partner at BCG India and Southeast Asia Healthcare Practice Leader, said India is witnessing a fundamental transformation “from replication to origination, and from process excellence to scientific discovery.” Similarly, Ajay Mahipal,
Co-Founder and General Partner at HealthKois, noted that India is creating a unique competitive advantage by combining cost efficiency, high-quality data, and scientific talent in ways few countries can match.

Based on insights gathered from more than 30 interviews with pharmaceutical executives, startup founders, investors, and industry experts, along with extensive analysis of patents, venture investments, innovation pipelines, and global datasets, the report concludes that India’s life sciences sector is entering a new phase of innovation-driven growth. As reported by thehindubusinessline.com, with continued investment, policy support, and stronger research capabilities, the country is well positioned to emerge as a major global centre for pharmaceutical innovation and advanced healthcare technologies.

MAIRE announced that its subsidiary Tecnimont, part of its Integrated Engineering & Construction (E&C) Solutions business, bagged a €1.3 billion contract from Fértil Pampa S.A.U., a wholly owned subsidiary of Pampa Energia S.A., to develop a large-scale fertilizer complex in Argentina. The project marks Tecnimont’s entry into the Argentine market and further strengthens MAIRE’s global footprint in delivering world-class industrial and fertilizer infrastructure.

Largest Urea Production Facility in Latin America

The fertilizer complex will be constructed on an 80-hectare site within the Bahía Blanca Industrial Complex in Buenos Aires Province. The facility will comprise a world-scale ammonia production facility, two parallel Ultra-Low Energy (ULE) urea production trains and dedicated granulation units for each production line. Together, the plant will have a production capacity of 6,000 metric tonnes per day, equivalent to 2.1 million tonnes of urea annually, making it the largest urea manufacturing facility in Latin America.

Strategic Location Enhances Operational Efficiency

The project site has been strategically selected adjacent to Pampa Energia’s existing power generation assets, enabling efficient integration with critical infrastructure. The location offers direct access to natural gas pipeline networks, high-voltage electricity transmission lines, industrial water intake systems and a deep-water export port. These advantages will improve logistics, reduce operating costs and facilitate efficient distribution of fertilizer products to domestic and international markets.

Tecnimont to Deliver Complete EPC Services

Under the contract, Tecnimont will execute the project’s Engineering, Procurement, Commissioning and plant start-up activities. The company will leverage its extensive experience in executing large-scale fertilizer and petrochemical projects to ensure efficient project delivery.

Advanced Technologies to Improve Energy Efficiency

The project will incorporate advanced technologies from several global technology providers. Nextchem, MAIRE’s sustainable technology business, will provide:

Stamicarbon’s market-leading urea melt licensing technology

Urea granulation technology

Process Design Package (PDP)

Proprietary process equipment

Additionally, KT Tech will supply the primary reformer for synthesis gas (syngas) production, while KBR will provide the ammonia production technology. Of the total €1.3 billion contract value, approximately €140 million relates to Nextchem’s technology package. The project will be executed in collaboration with SACDE S.A., one of Argentina’s leading construction companies. Construction is expected to be completed within 41 months, supporting the timely development of one of the region’s most significant fertilizer manufacturing investments.

MAIRE Expands Global Presence

Alessandro Bernini, Chief Executive Officer of MAIRE, said, “This award marks our entry into Argentina, further diversifying our geographical footprint. It also demonstrates our ability to combine Tecnimont’s proven project execution capabilities with Nextchem’s advanced technology portfolio to deliver world-scale industrial projects.” He added that the fertilizer complex will support the efficient utilisation of Argentina’s natural gas reserves while strengthening the country’s downstream fertilizer industry and long-term agricultural competitiveness.

Strengthening Sustainable Fertilizer Manufacturing

The project represents another important milestone for MAIRE in expanding its global engineering and sustainable technology business. By integrating advanced ammonia and ultra-low-energy urea production technologies, the facility is expected to improve energy efficiency while supporting sustainable fertilizer manufacturing. As per the press release, once operational, the complex will significantly strengthen Latin America’s fertilizer production capacity and contribute to regional food security through reliable domestic urea supply.